Early trial pairs radiation blitz with immune drug for tough liver cancer
NCT ID NCT04708067
Summary
This early-stage study is testing the safety and best dose of a two-part treatment for advanced bile duct cancer that has spread. Patients receive a short, intense course of radiation to one tumor, followed by an immunotherapy drug designed to help the immune system attack the cancer. The goal is to see if this combination can help control this difficult-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.